 |
27 Products |  |
14 Diseases | | 27 Products |
|
39 Trials |  |
6071 News |  |
| 12345678910111213...6566» |
- | Kymriah (tisagenlecleucel-T) / Novartis, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
Journal: Longitudinal analysis of lentiviral and retroviral chimeric antigen receptors' integration sites reveals distinct clonal evolutionary patterns. (Pubmed Central) - Apr 10, 2025
Gammaretroviral CARs had divergent outcomes: no detectable CAR (axicabtagene-ciloleucel) or low-level oligoclonal persistence (brexucabtagene-autoleucel). Whether this latter evolution is at risk of further CAR malignancies needs further investigations.
- | birinapant (IGM-9427) / IGM Biosciences
Journal: Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy. (Pubmed Central) - Apr 9, 2025
Finally, using both PDX and immunocompetent mouse models of GBM, we show that the SMAC mimetic birinapant, administered as an adjuvant after radiotherapy, can eliminate senescent GBM cells and prevent the emergence of recurrent tumors. Taken together, our results clearly indicate that significant improvement in GBM patient survival may become possible in the clinic by eliminating senescent cells arising after radiotherapy.
- || Kymriah (tisagenlecleucel-T) / Novartis, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
Clinical, Journal: Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. (Pubmed Central) - Apr 9, 2025
In this particularly high-risk cohort, Br-RT prior to CAR-T demonstrates an acceptable toxicity profile with favorable clinical outcomes when compared to historical controls. Comprehensive Br-RT and LDH normalization post-Br-RT may be associated with superior PFS and OS.
- | Kymriah (tisagenlecleucel-T) / Novartis, Tecartus (brexucabtagene autoleucel) / Gilead
Journal, CAR T-Cell Therapy: The present and future for CAR-T cell therapy in adult B-cell ALL. (Pubmed Central) - Apr 3, 2025
Advancements in CAR-T design beyond CD19 represent an ongoing therapeutic evolution. Overall, CAR-T therapy signifies a paradigm shift in B-ALL management, with the potential for improved remission and survival in a historically challenging patient population.
- || Kymriah (tisagenlecleucel-T) / Novartis, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
Review, Journal: Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma. (Pubmed Central) - Apr 2, 2025
In this review, we aim to define best practice for the referral and treatment of patients with R/R B-cell lymphoma with CAR T-cell therapy in Australia. We outline the processes for referral, optimal patient selection and best practice in the management of patients receiving CAR T cells.
- | Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Journal, Real-world evidence: Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience. (Pubmed Central) - Mar 30, 2025
Multivariate analysis identified RBT as independently associated with improved PFS (HR 0.46, 95% CI 0.22-0.96). Pending prospective validation, RBT shows promise for improving CAR-T outcomes in LBCL.
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, birinapant (IGM-9427) / IGM Biosciences
Preclinical, Journal: Birinapant improves imiquimod-induced psoriasis in BALB/c mice. (Pubmed Central) - Mar 27, 2025
Furthermore, Birinapant positively affected oxidative stress maintenance, suggesting its potential role in promoting skin health and homeostasis. By demonstrating birinapant's efficacy, this research paves the way for further studies that could lead to the development of more effective therapies for psoriasis.
- | Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Retrospective data, Journal: Neurotoxicity in Patients With CNS Lymphomas Treated With CAR T-Cell Therapy: A Study From the French Oculo-Cerebral Lymphoma Network. (Pubmed Central) - Mar 27, 2025
Special attention should be given to older patients with cognitive impairment who seem at greater risk of severe forms of neurotoxicity. Larger series are warranted to confirm these results.
- | Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
Journal: Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome. (Pubmed Central) - Mar 24, 2025
Larger series are warranted to confirm these results. Our results suggest that and that it is important to monitor iP kinetics more carefully because patients treated with ide-cel complicate severe hypophosphatemia, regardless of CRS severity.
- | Kymriah (tisagenlecleucel-T) / Novartis, Tecartus (brexucabtagene autoleucel) / Gilead, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal, Real-world evidence: Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. (Pubmed Central) - Mar 24, 2025
In multivariate analysis, low disease burden was associated with improved OS (HR 0.23, 95% CI 0.06-0.86, p=0.03), while inotuzumab pre-CAR T was associated with inferior outcomes (OS HR 6.32, 95% CI 1.48-27, p=0.01; RFS HR 3.65, 95% CI 1.41-9.46, p=0.008). This study demonstrates comparable real-world efficacy among young adults receiving CD19 CAR T therapy irrespective of CAR T construct, however, rates of toxicity appear higher with brexu-cel.
- | Kymriah (tisagenlecleucel-T) / Novartis
Enrollment closed: REFUEL: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov) - Mar 24, 2025
P2, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
This study demonstrates comparable real-world efficacy among young adults receiving CD19 CAR T therapy irrespective of CAR T construct, however, rates of toxicity appear higher with brexu-cel. Recruiting --> Active, not recruiting
- | Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Journal, IO biomarker: The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies. (Pubmed Central) - Mar 17, 2025
These findings offer mechanistic insight into the observed clinical differences between axi-cel (CD28-based) and tisa-cel (4-1BB-based)-treated B-cell lymphoma patients and advance our understanding on CAR-T resistance. Furthermore, we underscore the need for specific FMC63 epitope detection to deliver information on antigen levels accessible for CD19-CAR-T-cells.
- || itacitinib (INCB039110) / Incyte
P2 data, Journal: Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. (Pubmed Central) - Mar 16, 2025
P2
Importantly, itacitinib did not impact IEC therapy efficacy (objective response rate at 6 months: 39.1% for itacitinib 200 mg bid vs 26.1% for placebo). Trial registration: clinicaltrials.gov; #NCT04071366.
- | Kymriah (tisagenlecleucel-T) / Novartis, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series. (Pubmed Central) - Mar 14, 2025
Trial registration: clinicaltrials.gov; #NCT04071366. InO can be used successfully and safely for the treatment of CD22POS BCP-ALL relapse after tisagenlecleucel as a bridge to allo-HSCT in heavily pretreated pediatric patients.
- | Kymriah (tisagenlecleucel-T) / Novartis
Journal: Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey. (Pubmed Central) - Mar 11, 2025
InO can be used successfully and safely for the treatment of CD22POS BCP-ALL relapse after tisagenlecleucel as a bridge to allo-HSCT in heavily pretreated pediatric patients. The MSR (87.9
- birinapant (IGM-9427) / IGM Biosciences
Eliminating hepatitis B with a combination of the newly revised Entecavir and Birinapant (Poster Area) - Mar 8, 2025 - Abstract #EASL2025EASL_1936;
- | Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Retrospective data, Journal: Treatment outcomes of axicabtagene ciloleucel for relapsed/refractory diffuse large B-cell lymphoma: a retrospective analysis at a single institution (Pubmed Central) - Mar 6, 2025
The median follow-up period was 8.1 months (range, 1.0-23.2), and the 6-month progression-free survival and overall survival rates were 80.2% (95% confidence interval [CI], 58.8-91.3) and 92.0% (95%CI, 71.6-97.9), respectively. Although our study was limited by its small sample size and short follow-up period, it demonstrated that axi-cel was highly effective and safe at our institution.
- || HER-2 pulsed DC1 / ImmunoRestoration
Trial completion date, Trial primary completion date: NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov) - Mar 3, 2025
P2, N=53, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Although our study was limited by its small sample size and short follow-up period, it demonstrated that axi-cel was highly effective and safe at our institution. Trial completion date: Jan 2025 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Oct 2025
- | Ampligen (rintatolimod) / AIM ImmunoTech
Trial completion date, Trial primary completion date, IO biomarker: Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov) - Feb 26, 2025
P2, N=24, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Jan 2025 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Oct 2025 Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
- ||| Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Observational data, Journal, Adverse events: Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. (Pubmed Central) - Feb 25, 2025
This cohort study suggests that CAR T-cell therapy has a favorable safety profile. However, continuous follow-up of patients is needed, as serious AEs can occur years after infusion.
- Outcomes of CAR T-Cell Therapy in Pediatric & Young Adult With B-Cell Acute Lymphoblastic Leukemia : A Systematic Review (Poster 2 | Exhibition Room, No.3 Bldg. 1F, Kobe International Exhibition Hall) - Feb 22, 2025 - Abstract #JSMO2025JSMO_865;
- | Kymriah (tisagenlecleucel-T) / Novartis
Journal, IO biomarker: Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR-T Cells Against Hematological Malignancies. (Pubmed Central) - Feb 19, 2025
CAR-T cell therapy responders with large B-cell lymphoma. Collectively, these results demonstrate that targeting PRC2 may be a promising approach to enhance a functional effector program in CAR-T cells to improve the efficacy in treating hematological malignancies.
- | Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Journal: Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. (Pubmed Central) - Feb 17, 2025
bRT and CART is a good treatment strategy for select patients with aggressive B cell lymphoma. Comprehensive bRT including all sites of disease is associated with improved outcomes.
- || BNT163 / BioNTech
Trial completion date, Trial primary completion date: A Clinical Trial in Healthy Volunteers and Volunteers with Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination with an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - Feb 12, 2025
P1, N=308, Recruiting, Sponsor: BioNTech SE
Comprehensive bRT including all sites of disease is associated with improved outcomes. Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Apr 2026 --> Oct 2026
- | Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Journal: Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. (Pubmed Central) - Feb 12, 2025
In conclusion, CD19 CAR T-cell therapy infrequently delivers long term disease control in BL. Further investigation is needed to determine the most effective alternative management of these patients.
- |||||| SynKIR-110 / HLB Bio Group, SynKIR-310 / HLB Bio Group
Enrollment open: A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product (clinicaltrials.gov) - Feb 11, 2025
P=N/A, N=60, Enrolling by invitation, Sponsor: Verismo Therapeutics
Further investigation is needed to determine the most effective alternative management of these patients. Not yet recruiting --> Enrolling by invitation
- | Kymriah (tisagenlecleucel-T) / Novartis
Journal: Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS. (Pubmed Central) - Feb 6, 2025
Most CVAEs were associated with cytokine release syndrome, and older patients had a more favorable prognosis. Children and adolescents who receive tisagenlecleucel should be closely monitored for CVAEs, particularly during the first week of treatment.
- TRACKING THE PATIENT QUALITY OF LIFE JOURNEY WITH PROMIS-29 AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (Raffaello (Spadolini -1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3338;
Variability in summary and domain scores existed between products and timepoints, though most patients who answered showed improvement from standardized norms over time. This data can serve as a baseline for future interventions.
- Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
COMPARISON OF OUTCOMES AFTER CAR-T CELL THERAPY (TISAGENLECLEUCEL OR AXICABTAGENE CILOLEUCEL) IN PATIENTS AGED >70 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA: CTIWP-EBMT (Giotto (Spadolini -1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3334;
This data can serve as a baseline for future interventions. In conclusion, after Axi-cel infusion, elderly patients (> 70 y) had improved OS and PFS, decreased RI, despite higher toxicity (CRS and ICANS) when compared to those patients given Tisa-cel.
- COMORBIDITIES DO NOT AFFECT NON-RELAPSE MORTALITY OR TOXICITY IN CD19 CAR-T THERAPY: INSIGHTS FROM A MULTICENTER REAL-WORLD ANALYSIS (Giotto (Spadolini -1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3333;
Neither baseline unfitness nor comorbidities adversely affected treatment tolerability or NRM. Given the modest NRM rates compared to the high efficacy of CAR-T therapy, these treatments should be actively considered even for elderly or "unfit" patients.
- OUTCOMES OF CAR T-CELL THERAPY (CART19) FOR B-ALL: A GOCART COALITION REPORT ON BEHALF OF THE PDWP, ALWP, AND CTIWP OF THE EBMT (Giotto (S-1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3290;
A total of 345 B-ALL patients (173 adults and 172 paediatrics) received therapy with Kymriah (65%), ARI-0001 (26%), Tecartus (5.5%), and others (3.5%), with a reverse Kaplan-Meier median follow-up of 2.2 years...Notably, this association was lost in alloHCT-exposed patients, with no impact for prior blinatumomab exposure and response. Prior inotuzumab refractoriness was strongly associated with worse 2-year OS and LFS for both alloHCT-na
- EVALUATION OF COGNITIVE IMPAIRMENT AND NEUROTOXIC EFFECTS IN ADULT PATIENTS UNDERGOING CAR-T CELL THERAPY (Dante (Spadolini -1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3213;
Axicabtagene Ciloleucel was infused to 20 patients, Brexucabtagene Autoleucel to 4 patients, Tisagenlecleucel to 2 patients, Cilta-cel to 2 patients and PHE 885 to 2 patients according to disease indications. The lowest scores were identified 3 months after infusion irrespective of disease response or severe toxicities, indicating that further long-term studies are needed in this population.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
T-ICAHT: A NOVEL GRADING SYSTEM TO CHARACTERIZE THROMBOCYTOPENIA AND ITS PROGNOSTIC RELEVANCE IN CAR-T THERAPY (Raffaello (Spadolini -1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3181;
Using this system, we identified high-grade thrombocytopenia (G?3) in over 20% of patients. Importantly, T-ICAHT grades were prognostically significant, stratifying survival risk independently of established risk factors.
- Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
LATE HEMATOTOXICITY OF CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL IN PATIENTS WITH LARGE B CELL LYMPHOMA (LBCL): THE ANALYSIS OF CELL THERAPY CONSORTIUM (Raffaello (Spadolini -1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3178;
CAR HAEMATOTOX index is an independent predictor of late cytopenia after CD19 CAR T cell therapy. Clinical Trial Registry: Not applicable
- REAL WORLD INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL (Raffaello (Spadolini -1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3177;
Patients experienced heterogeneous clinical manifestations, mainly represented by fever and liver involvement. Anakinra and steroids represented the employed treatments and the overall survival was 80.9% at 90 days.
- Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
CD19.CAR-T DERIVED EXTRACELLULAR VESICLES: A NEW DYNAMIC BIOMARKER WITH A STRONG ANTILEUKEMIC ACTIVITY (Cavaniglia 2) - Feb 5, 2025 - Abstract #EBMT2025EBMT_3172;
CD19.CAR-T cell-derived EVs may be proposed as promising dynamic new biomarkers of CAR-T cell activity and, contributing to the direct killing of the leukemic target, represent a new product with a strong therapeutic potential that could be infused independently from CAR-T cells. CD19.CAR+EVs have the potential to be an 'off?the?shelf product'.
- Kymriah (tisagenlecleucel-T) / Novartis
ALLOGENEIC STEM CELL TRANSPLANTATION AFTER CAR-T CELL FOR R/R B-ALL IN PAEDIATRIC AND YOUNG ADULT PATIENTS. A RETROSPECTIVE STUDY ON BEHALF OF THE SPANISH GETH-TC (Firenze (S1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_2936;
Relapse after transplant is still a major concern and consolidation strategies should be considered. We could not demonstrate any subgroup of patients with higher risk of relapse after SCT, probably because of the variability of the risk factors in our cohort.
- Kymriah (tisagenlecleucel-T) / Novartis
ALLOGENEIC STEM CELL TRANSPLANTATION AFTER CAR-T CELL FOR R/R B-ALL IN PAEDIATRIC AND YOUNG ADULT PATIENTS. A RETROSPECTIVE STUDY ON BEHALF OF THE SPANISH GETH-TC (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_2935;
Relapse after transplant is still a major concern and consolidation strategies should be considered. We could not demonstrate any subgroup of patients with higher risk of relapse after SCT, probably because of the variability of the risk factors in our cohort.
- SURVEILLANCE AND PROPHYLAXIS OF INFECTIONS FOLLOWING CAR-T CELL THERAPY: INTERNATIONAL SURVEY ON BEHALF OF THE INFECTIOUS DISEASES WORKING PARTY AND GOCART COALITION EBMT (Firenze (Spadolini 1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_2381;
More outcome data are needed to generate better evidence-based recommendations. Continuous education on longitudinal infection risks and surveillance and management recommendations among CAR-T recipients is needed.
- SURVEILLANCE AND PROPHYLAXIS OF INFECTIONS FOLLOWING CAR-T CELL THERAPY: INTERNATIONAL SURVEY ON BEHALF OF THE INFECTIOUS DISEASES WORKING PARTY AND GOCART COALITION EBMT (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_2380;
More outcome data are needed to generate better evidence-based recommendations. Continuous education on longitudinal infection risks and surveillance and management recommendations among CAR-T recipients is needed.
- Kymriah (tisagenlecleucel-T) / Novartis, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
CAR T THERAPY IN SLOVAKIA: A SINGLE CENTRE EXPERIENCE (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1971;
This single-centre experience with CAR T-cell therapy supports real-world data from other countries. Despite the short follow-up, our findings confirm a significant clinical benefit for some patients who have exhausted conventional therapeutic modalities.
- Kymriah (tisagenlecleucel-T) / Novartis, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
BRAIN FDG-PET-MRI TO IDENTIFY NEUROTOXICITY AFTER CAR T-CELL THERAPY AND GUIDE TREATMENT: A PEDIATRIC CASE (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1965;
Sequential brain FDG-PET-MRI guided clinical decisions for management of ICANS in this patient for several months after CAR-T treatment. We suggest FDG-PET-MRI to be incorporated in the clinical assessment of ICANS in children, particularly when neurological alterations persist.
- Kymriah (tisagenlecleucel-T) / Novartis
IMPACT OF SARCOPENIA AND CYTOKINES ON CAR T OUTCOMES IN ADULTS WITH R/R DLBCL TREATED WITH TISAGENLECLEUCE (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1954;
GPS score of 2 was associated with inferior efficacy outcomes. Adults with BMI >30, higher median visceral fat and total fat index had lower levels of key inflammatory biomarkers including IL15 and GM-CSF.
- FROM TUMOR BOARD DECISION TO INFUSION: ARE TIMELINES OF ANTI-CD19 DIRECTED CAR-T CELL THERAPY AFFECTING THE TREATMENT OUTCOME? (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1953;
Adults with BMI >30, higher median visceral fat and total fat index had lower levels of key inflammatory biomarkers including IL15 and GM-CSF. In 66 patients (86.8%) bridging therapy was recorded: rituximab, polatuzumab vedotin
- Kymriah (tisagenlecleucel-T) / Novartis
A BI-CENTER REAL-WORLD DATA OF TISAGENLECLEUCEL VERSUS ALLOGENEIC HSCT OUTCOMES IN LARGE B-CELL LYMPHOMAS (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1949;
However, differences in patient characteristics between the two cohorts warrant cautious interpretation of these results. Allo-HSCT remains a viable option for younger, chemotherapy-responsive patients who are ineligible for CAR-T therapy.
- Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
CYTOKINE PROFILE AS A PREDICTOR OF CELLULAR EXPANSION AND ICANS IN CAR-T CELL THERAPY FOR B-CELL LYMPHOMAS (Firenze (Spadolini 1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1943;
We evaluated all B-cell lymphomas patients treated at our center with commercial CAR-T cells (Axi-cel, Brexu-cel, and Tisa-cel) from December 2021 to March 2024. The evaluation of the cytokine profile within our cohort of patients with B-cell lymphomas treated with CAR-T cells has proven to be an effective tool in predicting cellular expansion (IL-2RA) and neurological toxicity (IL-15, fractalkine, Nfl and IFN-?).
- Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
CYTOKINE PROFILE AS A PREDICTOR OF CELLULAR EXPANSION AND ICANS IN CAR-T CELL THERAPY FOR B-CELL LYMPHOMAS (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1942;
We evaluated all B-cell lymphomas patients treated at our center with commercial CAR-T cells (Axi-cel, Brexu-cel, and Tisa-cel) from December 2021 to March 2024. The evaluation of the cytokine profile within our cohort of patients with B-cell lymphomas treated with CAR-T cells has proven to be an effective tool in predicting cellular expansion (IL-2RA) and neurological toxicity (IL-15, fractalkine, Nfl and IFN-?).
- Kymriah (tisagenlecleucel-T) / Novartis
THIRD LINE (3L) CAR T-CELL THERAPY IN THE GOLDEN YEARS: A SINGLE-CENTER EXPERIENCE ON OUTCOMES FOR ELDERLY PATIENTS IN LARGE B-CELL LYMPHOMA (Firenze (Spadolini 1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1931;
CAR T-cell therapy shows similar OS, PFS, and toxicity outcomes in DLBCL patients aged ?70 compared to younger patients, suggesting that older patients can tolerate and benefit from CAR T-cell therapy effectively. Further research is needed in the selection for older patients used by referring physicians.
- Kymriah (tisagenlecleucel-T) / Novartis
THIRD LINE (3L) CAR T-CELL THERAPY IN THE GOLDEN YEARS: A SINGLE-CENTER EXPERIENCE ON OUTCOMES FOR ELDERLY PATIENTS IN LARGE B-CELL LYMPHOMA (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1930;
CAR T-cell therapy shows similar OS, PFS, and toxicity outcomes in DLBCL patients aged ?70 compared to younger patients, suggesting that older patients can tolerate and benefit from CAR T-cell therapy effectively. Further research is needed in the selection for older patients used by referring physicians.
- Kymriah (tisagenlecleucel-T) / Novartis
LOW DISEASE BURDEN BEFORE CAR-T CELL INFUSION HIGHLY REDUCES THERAPY-RELATED TOXICITIES (Firenze (Spadolini 1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1921;
Further research is needed in the selection for older patients used by referring physicians. Our cohort comprised 37 children diagnosed with pB-ALL (21 boys and 16 girls, aged 1.7 to 17.5 years) who received CAR-T cell therapy (tisagenlecleucel, Kymriah